Skip to main content
S&P 5007,663.60+0.95%DOW52,538.72+0.91%NASDAQ26,377.47+1.13%BTC$78,586.00+1.65%ETH$2,605.82+6.74%GOLD$4,411.90+0.10%OIL$99.61-2.80%
Smart Investors Daily
SR

NASDAQ · SRTS

Sensus Healthcare, Inc.

Healthcare · Medical - Devices

$3.12

Down-$0.01 (-0.32%)

Updated Sep 11, 2026, 3:16 PM

SID Score

5.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
63.07M
P/E ratio
-20.86
Dividend yield
0.00%
52-week range
$2.66 – $4.55
Volume
27.16K
Avg. volume
108.12K

Price performance

SRTS price history

1M range · 20 trading sessions · Daily adjusted prices

SRTS closed at $3.12 after 20 trading sessions, down 1.27% for the selected period.

Last close
$3.12
Period change
-1.27%
Period low
$2.86
Period high
$3.54
Daily close
View OHLC price history
SRTS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$3.12$3.15$3.06$3.1227.16K
Sep 9, 2026$3.16$3.16$3.12$3.1213.7K
Sep 8, 2026$3.25$3.3637$3.15$3.1624.01K
Sep 4, 2026$3.17$3.385$3.11$3.1916.5K
Sep 3, 2026$3.25$3.4636$3.1413$3.2625.4K
Sep 2, 2026$3.31$3.38$3.215$3.2522.08K
Sep 1, 2026$3.47$3.65$3.33$3.3388.42K
Aug 31, 2026$3.56$3.72$3.49$3.54139.94K
Aug 28, 2026$3.36$3.5799$3.2383$3.5299.64K
Aug 27, 2026$3.21$3.4398$3.155$3.3732.61K
Aug 26, 2026$3.32$3.3838$3.09$3.2929.61K
Aug 25, 2026$3.50$3.50$3.36$3.3644.62K
Aug 24, 2026$3.30$3.49$3.20$3.4982.31K
Aug 21, 2026$3.29$3.3429$3.13$3.3424.63K
Aug 20, 2026$2.98$3.25$2.8601$3.23103.03K
Aug 19, 2026$2.99$3.09$2.9707$3.0113.88K
Aug 18, 2026$2.90$3.025$2.89$3.0034.38K
Aug 17, 2026$2.85$2.93$2.85$2.9029.45K
Aug 14, 2026$2.80$2.98$2.80$2.8676.41K
Aug 13, 2026$3.19$3.34$3.02$3.1664.62K

Latest SRTS news

The latest Smart Investors Daily articles mentioning SRTS.

Stock researchCompany · Overview

SRTS research

Overview

Company profile and research snapshot.

Company profile

Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$10.00
Implied upside
—
Analysts
9
SRTS recent ratings
DateFirmRatingTarget
Aug 14, 2026Lake StreetBuy—
Feb 17, 2026Maxim GroupBuy—
Aug 12, 2025HC Wainwright & Co.Buy—
Aug 8, 2025Lake StreetBuy—
May 19, 2025Maxim GroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 26, 2026

Sensus Healthcare Introduces Sensus Link, Brings Advanced Operating Capabilities to the SRT-100™ Installed Base

BOCA RATON, Fla., February 26, 2026--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, introduces Sensus Link, a cloud-based software and connectivity solution intended to expand advanced operating capabilities across the Company’s SRT-100™ system installed base.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By